ticenter randomized clinical trial compared web-based monitoring vs standard scheduled imaging to detect symptomatic recurrence in patients with lung cancer following initial treatment. A planned interim analysis (9-month follow-up) found a significant survival benefit (19-month survival in the PRO group vs 12 months in the control group). 2 We now present the final overall survival analysis.
Methods | As described previously, 2 in this randomized trial, patients with advanced nonprogressive stage IIA (TXN1) to IV lung cancer were randomly assigned within 3 months of previous treatment to receive either web-based symptom monitoring via the Sentinel PRO system (Hyperion) or standard follow-up with scheduled imaging every 3 to 6 months (the trial protocol is available in Supplement 1). Eligible patients were recruited at 5 centers in France from June 2014 to January 2016. Nonprogressive patients treated for metastatic disease by tyrosine kinase inhibitors, maintenance antiangiogenic or chemotherapy, or immunotherapy were eligible. Allocation was generated centrally and concealed from investigators and participants. The study was reviewed and approved by the ethics review board from the University Hospital at Angers (France). All participants provided written informed consent. In the PRO group, patients were invited to complete weekly self-reports of 13 common symptoms online between visits. The PRO system automatically triggered an alert email to the treating oncologist when patient-reported symptoms matched predefined criteria for severity and worsening. In both groups, additional imaging could be performed at the treating oncologist's discretion.
The primary outcome was overall survival after 2 years of follow-up, which was selected based on prior pilot research. 3 Survival data were gathered from patient follow-up by blinded investigators. After a preplanned interim analysis in January 2016 in which a significant survival improvement was observed, the data and safety monitoring committee mandated cessation of recruitment and crossover of control patients to the intervention. Sixty percent of the prespecified sample size was enrolled when recruitment was halted. The final date of follow-up was December 29, 2017.
Overall survival was estimated via the Kaplan-Meier method and compared between groups with a log-rank test (SAS version 9.3; SAS Institute). A 2-sided P<.05 was considered significant. Analyses were performed on an intention-totreat basis and with censoring at crossover. 4 Results | One hundred thirty-three patients were enrolled of whom 12 were ineligible, leaving a study population of 121 (60 in the intervention and 61 in the control group) ( Figure 1 ). Baseline demographic and disease characteristics were well balanced between groups. 2 The median age was 65 years (range, 36-88 years), 67% were men, 32% had stage III cancer, 63% had stage IV cancer, and 17% had small cell cancer. Following interim analysis, 10 of 34 living patients in the control group had not relapsed and therefore were eligible to cross over to the intervention. No participants were lost to follow-up. With 2 years of follow-up, 69 deaths were observed: 29 (47.5%) in the intervention group and 40 (66.7%) in the control group. The median overall survival was 22.5 months in the intervention group vs 14.9 months in the control group, without censoring for crossover (hazard ratio, 0.59 [95% CI, 0.37-0.96]; P = .03) (Figure 2A ). Censoring crossover resulted in a median overall survival of 22.5 months in the intervention group vs 13.5 months in the control group (hazard ratio, 0.50 [95% CI, 0.31-0.81]; P = .005) ( Figure 2B ).
Discussion | Symptom monitoring via weekly web-based PROs following treatment for lung cancer was associated with increased survival compared with standard imaging surveillance. A potential mechanism of action is that symptoms suggesting adverse events or recurrence were detected earlier.
Limitations of this study include conduct only in France, early stopping of the trial and crossover of control patients, and inclusion of patients receiving maintenance therapy, who may have had increased interactions with care teams. I further agree that the investigators and other qualified members of my team will have access to the copies of this protocol and the documents relating to the conduct of the study, allowing them to work in accordance with the provisions contained in these documents. 
Coordinating investigator
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STUDY RATIONALE
LUNG CANCER
Lung cancer is the leading cause of cancer death in the world with 6 million deaths per year (1). In France, the incidence of lung cancer is estimated at 39,500 new cases in 2011. It represents each year nearly 11% of all new cases of cancer (11) . It is the second most common cancer for men and the third for women.
With a 5 year survival of around 15%, lung cancer is a cancer with a very poor prognosis. About 70 to 75% of cancers are diagnosed at advanced stages. Relapses are frequent and rarely curable. In France in 2011, more than 29,000 deaths are attributable to it, which represents nearly 20% of cancer deaths (11).
POST THERAPEUTIC SURVEILLANCE
At least 75% of relapses are symptomatic and there is no standard follow up after curative treatment or not (2 7). Currently, the most common surveillance strategy consists of performing a clinical examination every 3 to 6 months associated with chest x ray or CT scan. Intensive clinical and imaging follow up has not yet shown more advantage on survival, but symptom monitoring appears to have a significant medico economic advantage in comparison to imaging follow up (12) .
This non personalized approach is a source of anxiety (useless in the absence of relapse) for patients, especially as the imaging date approaches, or even weeks before the exams. In contrast, this surveillance may leave symptomatic patients with untreated relapse for several weeks because many symptomatic patients wait for the date of this assessment to consult (8) . This sometimes rapid deterioration of the general condition can reduce the accessibility to specific therapies and compromise the prognosis in the short or medium term. However, there is currently no evidence to suggest that earlier detection of relapse provides a benefit in survival.
"SENTINEL" TOOL FOR EARLY DETECTION OF LUNG CANCER RELAPSE
We developed a score based on the dynamic and the association of clinical signs to alert the physician of a possible relapse of lung cancer. The concerned variables are loss of weight, loss of appetite, dyspnea, asthenia, cough, pain, fever, hemoptysis, subcutaneous nodules, dysphonia and superior vena cava syndrome. These symptoms are self assessed by patients each week and sent by their smartphone or computer via the Internet and are analyzed by software that determines a high or low probability of relapse (8, 9) .
The referring physician is thus early alerted and summons the patient for a checkup. The prospective study of this application showed interesting results on these patients with a sensitivity of 100%, a specificity of 89%, a PPV of 81% and a NPV of 100% with 11 symptoms studied. In the initial study which aim is to establish an algorithm (validated by Pr Letellier's team, CNRS CORIA Rouen) for detection from only 6 symptoms, a NPV of 93% was already noted (8) . In addition, relapses were detected on average 5 weeks before the planned follow up assessment (imaging every 3 months) (9) SENTINEL Protocol 7/40 Version 5.0 January 03, 2018 An overall survival analysis (monocentric and non randomized) in our center also suggests a survival gain of nearly 24% at 1 year (p = 0.02) (F Denis et al, Supportive Care in Cancer, 2014) . In the follow up of the patients, it appeared that the algorithm was more sensitive if the patients were not much symptomatic at the inclusion and had an initial score lower than 7 (by adding the scores of 0 to 3 for the symptoms concerning the cough, dyspnea, pain, anorexia and asthenia: no problem = 0, slight problem = 1, medium problem = 2, major problem = 3 points) 
QUALITY OF LIFE / SURVIVAL AND EARLY SUPPORTIVE CARE
One of the explanations that could demonstrate this gain in survival is the possibility offered by the use of the SENTINEL application to treat relapses earlier and thus to avoid an excessive deterioration of the general condition between two monitoring visits more or less spaced out. This deterioration of the general state can, in only one month, make a patient, initially accessible to a specific care, in situation of not being able to receive specific treatment. In addition, the early management of symptoms reported by patients (pain, anorexia, dyspnea, depressive signs ...) via this Internet application is consistent to the results obtained in the study by Dr. Temel (NEJM 2010). In this study, patients with metastatic non small cells lung cancer were randomized between standard first line treatments to the same treatments plus monthly follow up by a supportive care team. This study showed a benefit in quality of life AND in survival, with a significant gain of 3 months of survival (10).
BENEFITS AND RISKS FOR STUDY SUBJECTS
1.5.1. Benefits
Individual benefits
The benefit expected for patients with the SENTINEL application will be mainly an earlier diagnosis of relapse and therefore more rapid specific treatment beginning which could have an impact on their survival but also on their quality of life via an early implementation of supportive care Beyond the benefit for patients in terms of survival and quality of life, the use of the SENTINEL application makes it possible to space out imaging follow up and thus to reduce the costs brought about compared to the standard follow up of the patients treated for lung cancer.
Risks
Individual risks  Constraints
Constraints are negligible and involved:
-to fill a quality of life questionnaire in at inclusion then at 3, 6 and 12 months, -to fill a depression questionnaire in at inclusion then at 3, 6 and 12 months, -for patients randomized in the "SENTINEL follow up" arm, to fill a specific questionnaire in weekly via a computer or smartphone.
There are no additional exams.
 Risks related to the disease
The risks of natural evolution of the disease are not modified by this study. 
Community risks
Benefit/risk balance
Standard follow up would have been proposed to all patients included in this study.
Given the study already carried out, it is unlikely that the relapse of cancer is diagnosed later with the SENTINEL application than during a standard follow up. Indeed, in the preliminary studies all relapses were symptomatic and the negative predictive value was 100%. It must be remembered that there is no standard of frequency and type of imaging in the monitoring of lung cancers. Indeed, in the "intensive follow up" arm of the IFCT 0302 study, imaging assessments were performed only every 6 months.
It is therefore expected that the use of the application SENTINEL will be beneficial for patients by allowing to detect earlier the relapse of lung cancer of patients included in the arm "SENTINEL".
DESCRIPTION AND JUSTIFICATION OF THE METHOD STUDIED
It is therefore a study which evaluate the optimization of the patients' follow up with lung cancer in order to extend the survival of the patients by improving their quality of life and reducing the anxiety generated by the realization of imaging exam. The spacing out of imaging exams during follow up would also reduce the cost of this follow up.
SENTINEL Protocol 9/40 Version 5.0 January 03, 2018
OBJECTIVES AND ENDPOINTS
PRIMARY OBJECTIVE AND ENDPOINT
Primary objective
The primary objective of the study is to evaluate overall survival.
Primary endpoint
Overall survival will be defined as the period from the date of random assignment to the date of death from any cause.
In this context, we will also evaluate the overall survival defined between the date of diagnosis and the date of death, in order to know more precisely the duration of the disease.
SECONDARY OBJECTIVES AND ENDPOINTS
Secondary objectives
We will evaluate too: -the quality of life, -the depression, -the relapse detection time -the PS at the relapse detection time, -the cost of the monitoring, -the patient's compliance, -the type of treatment begun at the relapse.
Secondary endpoints
Quality of life will be evaluated by FACT L questionnaire at inclusion, 3, 6 and 12 months. Scores will be calculated by the scoring guidelines of Facit.org.
Depression will be evaluated by PHQ9 questionnaire at baseline, 3, 6 and 12 months. Scores will be calculated by the scoring guidelines. The relapse detection time is defined by the time between the date of the diagnosis and the date of the first detected disease progression by imaging.
The Performance Status will be evaluated by the WHO's recommendations.
Cost effectiveness will be evaluated, first between the random assignment and the first event (a progression, a relapse or a death) or the last report for non relapsing living patients, we reported the number of (scheduled and unscheduled) visits to the oncologist and imaging for the two groups.
The compliance rate in the experimental arm will be evaluated (use of web application) by the ratio between the number of forms filled by the participants and the theoretical number of forms that the patients included should have filled.
The rate of optimal or non optimal treatment against this relapse will be reported by the investigator. An optimal treatment corresponds to a prescription for a patient with a PS equal to 0 or 1; a non optimal treatment is a reduced prescription due to poor physical conditions.
STUDY DESIGN
GENERAL STUDY METHODOLOGY
This is a prospective, multicenter, randomized, opened phase III study.
STUDY FLOWCHART
PATIENTS SELECTION
STUDY POPULATION
The population concerned includes all patients treated for a lung cancer and having an access to the internet.
We plan to include 224 patients during a 36 months period. 
INCLUSION CRITERIA
STUDY DESCRIPTION
STUDY CALENDAR
Screening and enrolment
Eligible patients will sign a consent form.
For inclusion, exams results (extension assessment for example) done before the consent form signature can be used if they were done in the timeline accept by the protocol.
Clinical exam
It contains a full medical examination with : Medical history Weight and PS Initial SENTINEL score at the inclusion
Imaging exam
Assessment have to be done in the 4 weeks before random assignment and the beginning of the follow up. It contains: At least a pulmonary CT scan (abdomen and cerebral if wanted) PET/CT 18 FDG according to lesions if negative CT scan Cerebral MRI if cerebral metastasis
Paraclinical checkup
It had to be done in the maximum 15 days before random assignment and the beginning of the follow up. Patients had to fill the following quality of life questionnaires in:
-FACT L, -HUMEUR PHQ9.
Assessment during the study
Patient follow up will be in accordance with the random assignment.
Whatever the randomized arm of the patient, he could receive appropriate supportive care for his situation. The necessity of supportive cares can be detected by the way of the medical consultation or by the way of the web application for patients in the "SENTINEL follow up" arm.
When questionnaire must be completed (programmed at M3, M6 or M12) but there isn't a medical visit, questionnaire had to be complete at patient's home and returned by post. These questionnaires must be always completed before imaging exam results to avoid patient to be influence by the imaging results.
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Arm A : standard follow up (control arm)
 Patients with non treatment follow up will visit physician every 3 months with:
-Clinical examination with PS estimation every 3 months during 2 years with pulmonary x ray if necessary -Cerebral, thorax and abdominal CT scan (or PET/CT or/and MRI according to the targets lesions saw or not in the CT scan) every 6 months during 2 years (except for patient with IIB/IV stage) -Fill the quality of life questionnaire in (FACT L) at M3, M6 and M12 follow up -Fill the HUMEUR PHQ9 questionnaire in (in relation with depression) at M3, M6 and M12 follow up
For patients with a IIIB/IV stage lung cancer, medical examination will be every 3 months (medical examination and PS estimation) with a cerebral, thorax and abdominal CT scan (or PET/CT or/and MRI according to the targets lesions saw or not in the scanner). For patients with stage IIIB / IV lung cancer, medical examination will be performed every 3 months (medical examination and PS assessment), a single imaging exam will be done at M12 in the case of no SENTINEL alert or no anomaly at medical examination. An assessment can be done if wanted by the physician, even if no SENTINEL alert.
Parallel, patients will realize a weekly self assessment by the SENTINEL web application. In order to do this, randomized patients will get an instruction mail to connect themselves in the application and an user manual of this application. Parallel, patients will realize a weekly self assessment by the SENTINEL web application. In order to do this, randomized patients will get an instruction mail to connect themselves in the application and an user manual of this application.
Imaging exam will be realized only if necessary (wishes of the physician, clinical anomaly with potential relapse, SENTINEL alert). One systematic medical imaging will be done at M12 if no SENTINEL alert or medical anomaly. 
SENTINEL follow up management
The investigator will consult SENTINEL application historic every day. In case of suspected relapse (due to the patient's answers on the application), an email alert will be sent to the investigator. More, a systematic mailing will be done the investigator if free text field is completed by the patient. If symptoms aren't seriousness, answer will be facultative, patient is informed of this possibility. But in case of a doubt, investigator will call the patient or ask patient to visit him for medical examination.
In case of a SENTINEL alert, investigator must: 1) Consult symptoms historic 2) Call patient to check lack of mistake in the input and lack of diet if weight loss 3) If confirmed doubt, call in the patient in maximum 7 days with a thorax abdominal CT scan (and cerebral if medical signs) 4) If negative CT scan, realize a PET (or lumbar puncture or MRI if neurologic signs or suspect pains)
If depression item is rated to 3, a psychologist consultation can be schedule. More, please note that a depressive syndrome can increase symptoms strength and weight loss and so disturb the analyze of the alert of the application.
For very significant symptoms, care supports can be suggesting, for example:
-If remain pains: alogologist consultation -If 3 kg weight loss or more and/or anorexia: dietician consultation -If increase of cough and dyspnea or hemoptysis: pulmonologist consultation
Decision making tree for SENTINEL alerts
Investigator will be mailing if patients don't complete application.
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TREATMENT DURING STUDY
In case of relapse, investigators will have the freedom to choose the treatment.
During the relapse treatment, whatever the randomized arm of the patient, investigator will have the freedom to program imaging exam as much as necessary.
However, for patients randomized in the SENTINEL arm, application follow up will be keep up during and after the treatment.
Supportive cares can be proposed in accordance with the clinical examination in the two arms of the study but also in accordance with SENTINEL alerts for the SENTINEL arm randomized patients (early adaptation of supportive cares according to patient's responses in the weekly questionnaire). After relapse treatment (for example after 4 or 6 cycles of chemotherapy), follow up will be the same that IIIB/IV stage patients: -Control arm, after relapse treatment, patient will get a CT scan every 3 months.
-SENTINEL arm, after relapse treatment, patient will get a CT scan only in case of SENTINEL alert or medical anomaly.
In case of maintenance therapy establishment, follow up will be the same as inclusion maintenance therapy arm. In case of TKI treatment establishment, follow up will be the same as inclusion TKI treatment arm.
IDENTIFICATION OF ALL DATA SOURCE NOT APPEARING IN THE MEDICAL FILE
Quality of life and depression questionnaires will not form part of the patient's source files. They will be made available in a sheet protector per patient in the investigative file so that they can be retranscribed in e CRFs.
In addition, self assessments completed by patients will not form part of the source files, and will be directly completed in the web application.
Other data concerning the patient, necessary for their follow up outside of the trial, will be collected in their medical file.
RULES FOR SUBJECT WITHDRAWAL
Criteria for a study subject's early withdrawal
Patients may withdraw their consent and ask to leave the trial at any time and for any reason, without losing the right to be treated by their doctor. The Investigator may also prematurely withdraw a patient from the trial for any reason which would best serve the interests of the patient, including a comorbid disease or an adverse event. In the event of early withdrawal, at any time and for any reason, the Investigator must inform the patient, if necessary, and document the reasons as fully as possible.
Withdrawals from the study must be reported, especially at the potential following reasons: death, patient refusal to continue the study, withdrawal of consent Investigator judgment, loss of contact.
Procedures for a study subject's early withdrawal
The means of medical care and follow up in the event of early withdrawal from the study for a given patient will be the same as the usual means outside of the Protocol.
Study termination criteria (excluding biostatistics considerations)
The last follow up visit of the last patient enrolled will determine the end of the study, corresponding to their follow up visit 24 months after enrolment.
In addition, the study may be terminated for administrative reasons and/or on Sponsor's decision. If the study is terminated early or suspended, the study manager will immediately inform the Ethics Committee (EC) of the reason for termination or suspension.
In all cases, enrolled patients will be followed up within the study until the study exit visit with the Investigator.
DATAMANAGEMENT AND STATISTICS
STUDY DATA COLLECTION AND PROCESSING
Data collection
An electronic case report form (e CRF) (ENNOV Clinical®, Floirac, France) will be created for each patient. All information required by the protocol must be provided in the e CRF. It will include the data necessary to confirm compliance with the protocol and identify any major gaps in the protocol, but also the data necessary for statistical analysis. 
Data coding
By signing this protocol, the principal investigator and all their co investigators undertake to keep confidential the identity of patients participating in the study.
Information required by the Protocol will be collected anonymously in the e CRF with an identification number for the site and a patient number. Only the first letters of the patient's surname and first name will appear. This code will be the only information appearing on the e CRF, enabling the e CRF to be correlated with the patient in retrospect.
The Investigator must ensure the anonymity of the patient. Therefore, patients must not be identified by name in the documents submitted to the Sponsor.
Data processing
For each patient, all the data will be collected in the e CRF. The e CRF will be completed by the investigator and / or a nurse that he will have designated for this task.
STATISTICS
Description of planned statistical methods
According to a phase II trial, the OS should be greater for patients in the experimental arm than for those in the standard arm; a one sided test is thus ethical to assess the OS. The sample size is computed using the R function "powersurvct.func".We assess that, at nine months, the OS rate could be equal to 82% with the web mediated follow up and 70% with the standard follow up. Thus, with the same number of patients in the two arms, the present study is designed to have 80% power to detect (with a type I error of 5%) a hazard ratio for death equal to 0.556. It is therefore required to observe 73 deaths.
An intermediate analysis is planned at the 37th recorded death allowing to stop the trial for ethical reasons if the p value is less than or equal to 0.006 (logrank test).
Analyses will be performed on an intention to test basis. All patients found to be ineligible after random assignment will be excluded of the analysis.
The baseline characteristics of the two groups will be presented with the effective and percentage for qualitative variables and continuous variables will be presented with median and range [Min Max].
Patients in the two arms will be compared with a Chis square test for categorical data and a non parametric Wilcoxon test for continuous variables.
The Kaplan Meier methodology will be used to summarize time to event variables. The number of patients with events and the number of censored patients will also be presented. Plots of Kaplan Meier product limit estimates of time to event will be drawn, medians will be presented in addition to confidence intervals, set at 95 percent.
Hazards ratio will be calculated using the univariate Cox proportional hazard model. A univariate analysis of variance was performed at baseline and at the second and third follow up for quality of life score, and depression score.
Quality of life scores will be calculated following the Facit.org guidelines in using the FACT L questionnaire.
Questionnaire completion rates will be calculated as a percentage of all patients who completed a questionnaire at a given time point. Completion rates and baseline quality of life scores (PWB, FWB, SWB, EWB, TOI, LCS, FACT G, FACT L) will be compared according to treatment arm.
The FACT L scores (PWB, FWB, SWB, EWB, TOI, LCS, FACT G, FACT L) will be described with mean, standard deviation, median and range. The ceiling and floor effect will be evaluated with frequency. Comparison at the baseline will be done, Wilcoxon non parametric test will be used. A longitudinal study with the help of mixed variance analyses to measure repetitions will be realized .
Statistical analyses will be performed using SAS 9.3 software (SAS Institute Inc, Cary, NC).
Healthcare cost
The main objective of the clinical study is to evaluate the overall survival of patients in both arms. The medico economic study conducted will be a cost effectiveness study (Drummond et al, 1987) . Its objective is to compare the costs of the two types of surveillance from the perspective of the Health Insurance. The cost items evaluated mainly correspond to consultations, imaging and, for the SENTINEL arm, the time mobilized for the management of the web application for the healthcare team.
Sample size
Based on the results from our earlier phase II trial, we hypothesized that the web mediated follow up would improve OS at nine months by 12% compared with standard follow up (82% vs 70%). Consequently, with a 1:1 random assignment, we planned to enroll 224 patients for detecting a hazard ratio for the OS equal to 0.55 (corresponding to 73 deaths) with a power of 80% and a one sided type I error of 5%.
Random assignment
Random assignment 1 : 1 will be perform according to a minimization with stratification on gender, age, PS, center, initial stage of the disease, treatment indication (adjuvant, 1 st line, 2 d line) and type of the taking care of (surveillance, maintenance, treatment by TKI). Random assignment is performed directly on the e CRF (ENNOV Clinical®, Cenon, France). The patient's arm of monitoring will be displayed instantly on the e CRF after performing the random assignment. A random assignment confirmation email will also be sent to the investigator. -for the treatment of a previous medical condition, -as an outpatient, not resulting in inpatient admission, -for the relapse or progression of the lung cancer, -for the cancer's treatment.
ADVERSE EVENTS HANDLING
SAE reporting
All SAEs (except as specified in section 7.1.4) require a SAE occurrence report (available in the e CRF) to be completed, whether the SAE is expected or unexpected. The Investigator must check that the information provided in the form is accurate and clear (with no abbreviations, etc.).
The SAE must be reported immediately (within 24 hours of the Investigator observing the SAE) to the Sponsor via the e CRF, then by fax at +33 2 41 68 29 79.
Independent Data Monitoring Committee
An IDMC with expertise and experience in the pathology, and without direct involvement in the conduct of the trial, will be set up, specifically to guarantee effective protection of patients, insure the ethical conduct of the trial, benefit/risk ratio of the trial, and to ensure the independent review of the scientific results during the trial and at the end of the trial.
The IDMC will be composed of : The charter of the IDMC is presented in annex.
TERMS AND DURATION OF SUBJECT FOLLOW UP AFTER THE OCCURRENCE OF ADVERSE EVENT
All enrolled patients will be followed up until the end of follow up appointment (corresponding to the follow up appointment taking place 24 months after enrolment).
ADMINISTRATIVE AND REGULATORY ASPECTS
RIGHT OF ACCESS TO SOURCE DATA AND DOCUMENTS
Before the start of the study, the Investigator is required to sign a Protocol signature page confirming his/her agreement to conduct the study in accordance with all the instructions and procedures appearing in this Protocol, and to provide access to all relevant data saved to the monitor CRAs, the auditors and the representatives of the regulatory authorities.
The medical data concerning each patient will only be sent to the Sponsor, the partner company developing the application or any person duly authorized thereby, and where applicable to the authorized health authorities, under conditions guaranteeing the confidentiality of the data.
The Sponsor and the supervisory authorities may request direct access to medical records to verify the clinical trial procedures and/or data, without breaching confidentiality and to the extent permitted by the laws and regulations.
Data collected during the trial may be subject to computer processing in accordance with the CNIL requirements (conformity to the reference methodology 001).
STUDY MONITORING
The study will be monitored by the Sponsor (by ICO until December 03, 2017 thus by Weprom following the sponsoring transfer) . The Sponsor will regularly conduct quality control on the data reported in the e CRFs. The monitoring will take place as follows, with visits to each site at least once then regularly according to the site enrolment numbers with monitoring of the following data :
1) The existence of the included patients 2) The collection of signed informed consents and their archiving 3) Respect of the eligibility criteria (inclusion and non inclusion) 4) The presence of the primary endpoint Collection of imaging reports 5) Reporting and Monitoring of Adverse Events Serious Adverse Events (SAE) New facts
The CRAs must be able to consult: -the data collection forms for enrolled patients, -patients' medical and nursing records, -the Investigator's file.
Additional remote visits may be made.
The Investigator must devote the necessary time for these visits. S/he must also ensure that the monitor has free access to the source documents (i.e. the patient clinical record, original laboratory and radiology tests, etc.) that support the data contained in the case report form SENTINEL Protocol 28/40 Version 5.0 January 03, 2018
INSPECTIONS / AUDIT
As part of this study, an inspection or audit may take place. The Sponsor will be responsible for preparing this audit or inspection, for ensuring access to all the study data and for verifying all the source data.
ETHICAL ASPECTS
Written informed consent
The Investigator undertakes to inform patients clearly and fairly of the Protocol and to request from them a written informed consent form (the information sheet and consent collection form are attached below).
The Investigator must give the patient one copy of the information sheet and one copy of the consent form. The patient may only be enrolled in the study after having read the information sheet and having signed and dated the consent collection form. The Investigator must also sign and date the consent collection form. The Investigator's original copy will be archived in the Investigator file.
The means of obtaining informed consent must be documented in the patient's medical records.
Ethics committee
The study draft must be submitted in advance for authorization from an EC. The information provided relates to both the terms and type of the study, and to the safeguards for patients participating in this trial.
The Ethics Committee (CPP Ouest II, ANGERS, France) issued a favorable opinion on this study on April 04, 2014.
AMENDMENTS TO THE PROTOCOL
Substantial amendment applications must be made by the Sponsor for authorization from or information to the EC in question, pursuant to Law 2004 806 of August 9, 2004 and its application Decree.
An updated and dated version of the amended Protocol must be submitted.
The patient information and consent collection forms may be subject to amendment if required
DECLARATION TO THE COMPETENT AUTHORITIES
The ANSM granted authorization to conduct this study on May 02, 2014.
FUNDING AND INSURANCE
The Sponsor has made a partnership for funding the study. The Sponsor has taken out an insurance policy with the SHAM (policy n°138926) guaranteeing the financial consequences of their civil liability in accordance with the regulations.
RULES FOR PUBLICATION
All the information resulting from this trial is considered confidential, at least until appropriate analysis and checking by the Sponsor, the Coordinating Investigator and the trial statistician have been completed.
All publications, abstracts or presentations including the results of the trial must be submitted for approval to the Sponsor (WeproM) and to SIVAN Innovation.
Furthermore, all communications, manuscripts or presentations must include a section referring to WeproM, all the institutions, Investigators, cooperative groups and academic societies that contributed to the conduct of the trial, and to the organization that financially supported the study.
For the main publication, in French or in English, the authors are: (to be confirmed depending on the trial and the partners participating in the study).
For example: -the study coordinator (first author or last author); -the Investigators who recruited the most patients (cited in order of recruitment numbers), regardless of the cooperative group of which they are members; -the Study statistician; -a representative of the Sponsor.
Similarly, the publication of annex results must include the name of the person who performed the complementary work and the name of any other person concerned by this work. In the event of a dispute, the order of the authors will be arbitrated by the Promoter (WeproM).
